Amgen Inc. (AMGN)

About Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

As of November 3, 2026, Amgen Inc. (AMGN) stock edged lower to $464.94, down 0.11% (-$0.51) versus the previous close. On the day, shares have traded between $461.40 and $466.94. That puts AMGN near the top of its 52-week range of $294.48 to $475.65. Amgen Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $251.64 billion, with about 134.6K shares changing hands.

Latest AMGN news

• Spdr Dow Jones Industrial Avg ETF (DIA) Sells Goldman Sachs and Caterpillar on Oct. 30Yahoo Finance· Nov 3, 6:05 AM ETDIA
• Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?trefis.com· Nov 2, 3:21 PM ET
• Amgen Just Gave Its Shareholders Great Newsfool.com· Nov 2, 12:45 PM ET
• Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?Yahoo Finance· Nov 2, 11:22 AM ET
• RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA PipelinesYahoo Finance· Nov 2, 10:50 AM ET
• Amgen (AMGN) Gets FDA Warning Letter Over Misleading Vectibix PromotionYahoo Finance· Nov 2, 10:06 AM ET
• Eli Lilly Jumped 6% After Earnings. It’s Up 68% in a Year. Where Does the Target Go Now?247wallst.com· Nov 2, 8:47 AM ET
• Tech Rebound, Crude Slide Lift Wall Street Pre-Bell; Asia Mixed, Europe UpYahoo Finance· Nov 2, 6:35 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want AMGN headlines, alerts and AI research in one place? Create a free account →

• 💥S&P 500 returns by days of the week YTD through 10 months. Election day is upon us along with over $10 trillion in market cap earnings announcements. $AAPL $PLTR $SHOP sharply lower premarket with $AMD $AMGN reporting after the close.

  @AnomalyDetective· Nov 3, 8:56 AM ET

• $ABCL $REGN $MRNA $SLS $AMGN $ABCL ABcellera 🔥 🔥 !!! There is some new data but it’s all 4 week data. Nothing has changed. I think most people don’t realize that the data we have right now, if it holds, is transformative for menopause industry. Transformative. That’s not eve…

  @Stocktradesmoon· Nov 3, 8:36 AM ET· Bullish

• AMD AMC is the AI test: FJElite sidebar pegs EPS $1.96 / rev $13.07B, with 30-day implied vol 19.29% — biggest expected move in Mag7+AMD; ANET, SMCI, $AMGN also report after the close (via @DeItaone). (7/8)

  @StockPlaza· Nov 3, 6:57 AM ET

• https://www.cnbc.com/2026/11/02/tuesdays-big-stock-stories-whats-likely-to-move-the-market.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $AMD $AMGN $XYZ Big earnings after the bell on ‘Closing Bell: Overtime’ Amgen is up 21% in three months. The stock …

  @parcha· Nov 3, 5:46 AM ET

• $AMGN reports third-quarter earnings on Tuesday, November 3, 2026 after the close, with its call at 4:30pm ET. Analysts expect EPS (profit per share) of about $5.79 on revenue near $10.07B, and options pricing points to a move of about 5% either way. A stock's value is not…

  @Techdamentals· Nov 2, 10:21 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →